Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England

References

• Apaydin, S. A., Uyar, M. U., Karabay, N. K., Erhan, E. E., Yegul, I. Y., & Teglular, I. T. (2000). The antinociceptive effect of tramadol on a model of neuropathic pain in rats. Life Sciences, 66(17), 1627–1637. https://doi.org/10.1016/S0024-3205(00)00482-3
   PubMed Web of Science ®Google Scholar
• Attal, N., Mazaltarine, G., Perrouin-Verbe, B., & Albert, T. (2009). Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous). Annals Of Physical And Rehabilitation Medicine, 52(2), 124–141. https://doi.org/10.1016/j.rehab.2008.12.011
   PubMedGoogle Scholar
• Bank of England. (2021). https://www.bankofengland.co.uk/monetay-policysummary-and-minutes/2021/december-2021.
   Google Scholar
• Benedict, R. H., Holtzer, R., Motl, R. W., Foley, F. W., Kaur, S., Hojnacki, D., … Weinstock-Guttman, B. (2011). Upper and lower extremity motor function and cognitive impairment in multiple sclerosis. Journal of the International Neuropsychological Society, 17(4), 643–653.
   PubMed Web of Science ®Google Scholar
• Bradley, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., & Fowler, C. J. (2004). An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis Journal, 10(4), 425–433. https://doi.org/10.1191/1352458504ms1063oa
   PubMed Web of Science ®Google Scholar
• Carotenuto, A., Signoriello, E., Lanzillo, R., Vaia, Y., Moccia, M., Bonavita, S., … Morra, V. B. (2020). Unravelling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 43, 102211.
   PubMed Web of Science ®Google Scholar
• Cochran. (2022). https://www.cochranelibrary.com/central/doi/10.1002central/CN-02341253/related-content?cookiesEnabled.
   Google Scholar
• Collin, C. C., Davies, P. D., Mutiboko, I. K. M., & Ratcliffe, S. R. (2007). Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. European Journal of Neurology, 14(3), 290–296. https://doi.org/10.1111/j.1468-1331.2006.01639.x
   PubMed Web of Science ®Google Scholar
• Duehmke, R. M. D., Derry, S. D., Wiffen, P. J. W., Bell, R. F. B., Aldington, D. A., & Moore, R. A. M. (2017). Tramadol for neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2017(6), https://doi.org/10.1002/14651858.CD003726.pub4
   Google Scholar
• Dutta, R., & Trapp, B. D. (2011). Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Progress in Neurobiology, 93(1), 1–12. https://doi.org/10.1016/j.pneurobio.2010.09.005
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. (2015). The Electronic Medicines Compendium. (2019). Sativex Oromucosal Spray.
   Google Scholar
• Electronic Medicines Compendium. (2019). The Electronic Medicines Compendium. (2019). Sativex Oromucosal Spray. https://www.medicines.org.uk/emc.
   Google Scholar
• Ferrè, L. F., Nuara, A. N., Pavan, G. P., Radaelli, M. R., Moiola, L. M., Rodegher, M. R., & Colombo, B. C. (2016). Efficacy and safety of nabiximols (sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurological Sciences, 37(2), 235–242. https://doi.org/10.1007/s10072-015-2392-x
   PubMed Web of Science ®Google Scholar
• Flachenecker, P. (2013). A new multiple sclerosis spasticity treatment option: Effect in everyday clinical practice and cost-effectiveness in Germany. Expert Review of Neurotherapeutics, 13(1), 15–19. https://doi.org/10.1586/ern.13.1
   PubMedGoogle Scholar
• Hilliard, A., Stott, C., Wright, S., Guy, G., Pryce, G., Al-Izki, S., Bolton, C., & Giovannoni, G. (2012). Evaluation of the effects of sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: A model of multiple sclerosis. ISRN Neurology, 2012, 802649. https://doi.org/10.5402/2012/802649
   PubMedGoogle Scholar
• Huang, W., Chen, W., & Zhang, X. (2017). Multiple sclerosis: Pathology, diagnosis and treatments. Experimental and Therapeutic Medicine, 13(6), 3163–3166. https://doi.org/10.3892/etm.2017.4410
   PubMed Web of Science ®Google Scholar
• Jouanjus E., Sans-Pola C., Alcubilla P., Mainoli B., Belancic A., Javid F. A., Ekheden I., & the EACPT Early Career Clinical Pharmacologist Working Group (2023). Perception of medical cannabis and other cannabis-based products by multidisciplinary healthcare professionals across Europe: A research project conducted by the European Association for Clinical Pharmacology and Therapeutics (EACPT) Early Career Clinical Pharmacologists. WCP2023. Glasgow, UK.
   Google Scholar
• Kavia, R. B. C., Ridder, D. D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). Randomized controlled trial of sativex to treat detrusor overactivity in multiple sclerosis. Multiple Sclerosis Journal, 16(11), 1349–1359. https://doi.org/10.1177/1352458510378020
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen, N., & Sørensen, P. S. (2010). The changing demographic pattern of multiple sclerosis epidemiology. The Lancet Neurology, 9(5), 520–532. https://doi.org/10.1016/S1474-4422(10)70064-8
   PubMed Web of Science ®Google Scholar
• Lamana, S. M. S., Napimoga, M. H., Nascimento, A. P. C., Freitas, F. F., de Araujo, D. R., Quinteiro, M. S., Macedo, C. G., Fogaça, C. L., & Clemente-Napimoga, J. T. (2017). The anti-inflammatory effect of tramadol in the temporomandibular joint of rats. European Journal Of Pharmacology, 807, 82–90. https://doi.org/10.1016/j.ejphar.2017.04.012
   PubMed Web of Science ®Google Scholar
• Lanzillo, R., Chiodi, A., Carotenuto, A., Magri, V., Napolitano, A., Liuzzi, R., … Morra, V. B. (2016). Quality of life and cognitive functions in early onset multiple sclerosis. European Journal of Paediatric Neurology, 20(1), 158–163.
   PubMed Web of Science ®Google Scholar
• Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del, U., Stefano, C., & Giancarlo, S. (2015). Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. Journal of Neurology, 262(11), 2520–2527. https://doi.org/10.1007/s00415-015-7878-1
   PubMed Web of Science ®Google Scholar
• Lu, L., Pearce, H., Roome, C., Shearer, J., Lang, I. A., & Stein, K. (2012). Cost effectiveness of oromucosal cannabis-based medicine (sativex®) for spasticity in multiple sclerosis. Pharmacoeconomics, 30(12), 1157–1171. https://doi.org/10.2165/11598470-000000000-00000
   PubMed Web of Science ®Google Scholar
• Markov, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., … Vila, C. (2019). Sativex as add-on therapy vs. further optimized first-line Antispastics (SAVANT) in resistant multiple sclerosis spasticity: a double -blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience, 129(2), 119–128.
   PubMed Web of Science ®Google Scholar
• Markovà, J., Essner, U., Akmaz, U., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019). Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: A double-blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience, 129(2), 119–128. https://doi.org/10.1080/00207454.2018.1481066
   PubMed Web of Science ®Google Scholar
• Messina, S., Solaro, C., Righini, I., Bergamaschi, R., Bonavita, S., Bossio, R. B., et al. (2017). Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study). PLoS One, 12, e0180651.
   Web of Science ®Google Scholar
• MHRA. (2021). About Yellow Card. Yellow Card. https://yellowcard.mhra.gov.uk/the-yellow-card-scheme/.
   Google Scholar
• MS Scoeity UK. (2024). Available from: https://www.mssociety.org.uk/what-we-do/news/approved-denied#:~:text=%E2%80%9CRight%20now%2C%20some%20people%20with,to%20provide%20the%20same%20dose. Accessed on 23rd March 2024.
   Google Scholar
• MS Trust. (2019). Sativex (Nabiximols). https://www.mstrust.org.uk/a-z/Sativex-nabiximols.
   Google Scholar
• NHS. (2018). Treatment -Multiple sclerosis. https://www.nhs.uk/conditions/multiple-sclerosis/treatment/.
   Google Scholar
• NHS BSA. (2020). Drug Tariff. Drug Tariff. https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff.
   Google Scholar
• NICE. (2017). What is an adverse drug reaction?. https://cks.nice.org.uk/topics/adverse-drug-reactions/background-information/definition/
   Google Scholar
• NICE. (2019). Managing multiple sclerosis symptoms. https://pathways.nice.org.uk/pathways/multiple-sclerosis.
   Google Scholar
• NICE. (2021). https://www.nice.org.uk.
   Google Scholar
• Novotna, A. N., Mares, J. M., Ratcliffe, S. R., Novakova, I. N., Vachova, M. V., Zapletalova, O. Z., & Davies P. D. (2011). A randomized, double-blind, placebo-controlled, parallel-group,enriched-design study of nabiximols* (Sativexâ), as add-ontherapy, in subjects with refractory spasticity caused by multiplesclerosis. European Journal of Neurology, 18(9), 1122–1131. https://doi.org/10.1111/j.1468-1331.2010.03328.x
   PubMed Web of Science ®Google Scholar
• Nuara, A., Pavan, G., Radaelli, M., Moiola, L., Ferre, L., Rodegher, M., & Esposito, F. (2016). Efficacy and safety of nabiximols (sativex Ò) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurological Sciences, 37(2), 235–242. https://doi.org/10.1007/s10072-015-2392-x
   PubMed Web of Science ®Google Scholar
• Nurmikko, T. J. N., Serpell, M. G. S., Hoggart, B. H., Toomey, P. J. T., Morlion, B. J. M., & Haines, D. H. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain, 133(1-3), 210–220. https://doi.org/10.1016/j.pain.2007.08.028
   PubMed Web of Science ®Google Scholar
• Patti, F., Messina, S., Solaro, C., Amato, M. P., Bergamaschi, R., Bonavita, S., Bruno Bossio, R., Brescia Morra, V., Costantino, G. F., Cavalla, P., Centonze, D., Comi, G., Cottone, S., Danni, M., Francia, A., Gajofatto, A., Gasperini, C., Ghezzi, A., Iudice, A., … Zappia, M. (2016). Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery & Psychiatry, 87(9), 944–951. https://doi.org/10.1136/jnnp-2015-312591
   PubMed Web of Science ®Google Scholar
• Pingel, J., Nielsen, M. S., Lauridsen, T., Rix, K., Bech, M., Alkjaer, T., … Feidenhasl, R. (2017). Injection of high dose of botulinum -toxin A leads to impaired skeletal muscle function and damage of the fibrillar and non-fibrilar structures. Scientific Reports, 7(1), 14746.
   PubMedGoogle Scholar
• Public Health England. (2020). Multiple sclerosis: prevalence, incidence and smoking status - data briefing. https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-incidence-and-smoking-status/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing.
   Google Scholar
• Rekand, T. (2014). Thc:CBD spray and MS spasticity symptoms: Data from latest studies. European Neurology, 71(suppl 1), 4–9. https://doi.org/10.1159/000357742
   PubMedGoogle Scholar
• Rekand, T. (2014). THC:CBD spray and MS spasticity symptoms: Data from latest studies. European Journal of Neurology, 71, 4–9.
   Google Scholar
• Rog, D. J., Nurmiko, T. J., Friede, T., & Young, C. A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65(6), 812–819. https://doi.org/10.1212/01.wnl.0000176753.45410.8b
   PubMed Web of Science ®Google Scholar
• Royal Pharmaceutical Society. (2019). Medicines, Ethics and Practice (MEP). https://www.rpharms.com/publications/the-mep.
   Google Scholar
• Russo, M., Calabrò, R. S., Naro, A., Sessa, E., Rifici, C., D’Aleo, G., Leo, A., De Luca, R., Quartarone, A., & Bramanti, P. (2015). Sativex in the management of multiple sclerosis-related spasticity: Role of the corticospinal modulation. Neural Plasticity, 2015(656582), 1–6. https://doi.org/10.1155/2015/656582
   Google Scholar
• Santoro, M., Mirabella, M., De Fino, C., Bianco, A., Lucchini, M., Losavio, F., Sabino, A., & Nociti, V. (2017). Sativex® effects on promoter methylation and on CNR1 / CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients. Journal Of The Neurological Sciences, 379, 298–303. https://doi.org/10.1016/j.jns.2017.06.017
   PubMed Web of Science ®Google Scholar
• Serpell, M. G., Notcutt, W., & Collin, C. (2013). Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis. Journal of Neurology, 260(1), 285–295. https://doi.org/10.1007/s00415-012-6634-z
   PubMed Web of Science ®Google Scholar
• Slof, J., & Gras, A. (2012). Sativex® in multiple sclerosis spasticity: A cost–effectiveness model. Expert Review of Pharmacoeconomics & Outcomes Research, 12(4), 439–441. https://doi.org/10.1586/erp.12.40
   PubMed Web of Science ®Google Scholar
• Slof, J., Ruiz, L., & Vila, C. (2015). Cost-effectiveness of sativex in multiple sclerosis spasticity: New data and application to Italy. Expert Review of Pharmacoeconomics & Outcomes Research, 15(3), 379–391. https://doi.org/10.1586/14737167.2015.1025759
   PubMed Web of Science ®Google Scholar
• Squintani, G., Donato, F., Turri, M., Deotto, L., Teatini, F., Moretto, G., & Erro, R. (2016). Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray. Journal of the Neurological Sciences, 370, 263–268. https://doi.org/10.1016/j.jns.2016.09.054
   PubMed Web of Science ®Google Scholar
• Syed, Y. Y., McKeage, K., & Scott, L. J. (2014). Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs, 74(5), 563–578. https://doi.org/10.1007/s40265-014-0197-5
   PubMed Web of Science ®Google Scholar
• Thibault, K., Calvino, B., & Pezet, S. (2011). Characterisation of sensory abnormalities observed in an animal model of multiple sclerosis: A behavioural and pharmacological study. European Journal of Pain, 15(3), 231.e1–16. https://doi.org/10.1016/j.ejpain.2010.07.010
   PubMed Web of Science ®Google Scholar
• Thompson, A. T., Baranzini, S. B., Geurts, J. G., Hemmer, B. H., & Ciccarelli, O. C. (2018). Multiple sclerosis. The Lancet, 391(10130), 1. https://doi.org/10.1016/S0140-6736(18)30481-1
   PubMed Web of Science ®Google Scholar
• Turri, M., Teatini, F., Donato, F., Zanette, G., Tugnoli, V., Deotto, L., & Squintani, G. (2018). Pain modulation after oromucosal cannabinoid spray (SATIVEX®) in patients with multiple sclerosis: A study with quantitative sensory testing and laser-evoked potentials. Medicines (Basel, Switzerland), 5(3), 59. https://doi.org/10.3390/medicines5030059
   PubMedGoogle Scholar
• Turri, M., Teatini, F., Donato, F., Zanette, G., Tugnoli, V., Deotto, L., … Squintani, G. (2018). Pain modulation after oromucosal cannabinoid spray (SATIVEX®) in patients with multiple sclerosis: A study with quantitative sensory testing and laserevoked potentials. Medicines, 5, 59.
   Google Scholar
• Vachová, M. V., Novotná, A. N., Mares, J. M., Taláb, R. T., Fiedler, J. F., Lauder, H. L., & Nováková, I. N. (2014). A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis. Journal of Multiple Sclerosis, 1(2), 1–2. http://doi.org/10.4172/jmso.1000122
   Google Scholar
• Ward, M., & Goldman, M. D. (2022). Epidemiology and pathophysiology of multiple sclerosis. Continuum, 28(4), 988–1005.
   PubMedGoogle Scholar
• Ward, M., & Goldman, M. D. (2022). Epidemology and pathophysiology of multiple sclerosis. Multiple Sclerosis and Relatyed Disorders, 28(4), 988–1005.
   Google Scholar
• Zajicek, J. P. (2005). Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. Journal of Neurology, Neurosurgery & Psychiatry, 76(12), 1664–1669. https://doi.org/10.1136/jnnp.2005.070136
   PubMed Web of Science ®Google Scholar
• Zajicek, J. P. Z., Hobart, J. C. H., Slade, A. S., Barnes, D. B., & Mattison, P. G. M. (2012). Multiple sclerosis and extract of cannabis: Results of the MUSEC trial. Journal of Neurology, Neurosurgery & Psychiatry, 83(11), 1125–1132. https://doi.org/10.1136/jnnp-2012-302468
   PubMed Web of Science ®Google Scholar
• Zephir, H. Z. (2018). Progress in understanding the pathophysiology of multiple sclerosis. Revue Neurologique, 174(6), 358–363. https://doi.org/10.1016/j.neurol.2018.03.006
   PubMed Web of Science ®Google Scholar